Literature DB >> 10918764

Bladder cancer: a review of diagnosis and management.

M C Metts1, J C Metts, S J Milito, C R Thomas.   

Abstract

Bladder cancer is the fourth most commonly diagnosed malignancy in men and the eighth most common in women. It represents a spectrum of disease, ranging from superficial, well-differentiated disease, which does not significantly impact survival, to highly malignant tumors for which long term survival may be dismal. Transitional-cell carcinoma, which constitutes the vast majority of bladder cancers in the United States, may develop as carcinoma in situ or as invasive carcinoma. This article focuses on transitional-cell carcinoma with a review of the major aspects of the disease, including the epidemiology, diagnosis and staging, and management (including organ preservation). Therapeutic options are explored, including surgery, radiotherapy, chemotherapy, and combined modality therapy.

Entities:  

Mesh:

Year:  2000        PMID: 10918764      PMCID: PMC2640522     

Source DB:  PubMed          Journal:  J Natl Med Assoc        ISSN: 0027-9684            Impact factor:   1.798


  53 in total

Review 1.  Treatment of T3 bladder cancer: controlled trial of pre-operative radiotherapy and radical cystectomy versus radical radiotherapy.

Authors:  H J Bloom; W F Hendry; D M Wallace; R G Skeet
Journal:  Br J Urol       Date:  1982-04

2.  Preliminary results of M-VAC (methotrexate, vinblastine, doxorubicin and cisplatin) for transitional cell carcinoma of the urothelium.

Authors:  C N Sternberg; A Yagoda; H I Scher; R C Watson; T Ahmed; L R Weiselberg; N Geller; P S Hollander; H W Herr; P C Sogani
Journal:  J Urol       Date:  1985-03       Impact factor: 7.450

3.  Total cystectomy for bladder cancer.

Authors:  V K Mathur; H P Krahn; E W Ramsey
Journal:  J Urol       Date:  1981-06       Impact factor: 7.450

4.  The value of preoperative classification according to the TNM system. A critical examination of Category T2 in 96 patients with grade 3 transitional cell bladder carcinoma subjected to preparative irradiation and cystectomy.

Authors:  H Wijkström; F Edsmyr; B Lundh
Journal:  Eur Urol       Date:  1984       Impact factor: 20.096

5.  Treatment of invasive bladder cancer by local resection and high dose methotrexate.

Authors:  R R Hall; D W Newling; P D Ramsden; B Richards; M R Robinson; P H Smith
Journal:  Br J Urol       Date:  1984-12

6.  Invasive bladder cancer: tumor configuration, lymphatic invasion and survival.

Authors:  N M Heney; K Proppe; G R Prout; P P Griffin; W U Shipley
Journal:  J Urol       Date:  1983-11       Impact factor: 7.450

7.  Radical cystectomy without radiation therapy for carcinoma of the bladder.

Authors:  J E Montie; R A Straffon; B H Stewart
Journal:  J Urol       Date:  1984-03       Impact factor: 7.450

8.  Five-year follow-up results of a collaborative study of therapies for carcinoma of the bladder.

Authors:  N H Slack; I D Bross; G R Prout
Journal:  J Surg Oncol       Date:  1977       Impact factor: 3.454

9.  Transitional cell carcinoma of the bladder in children and adolescents.

Authors:  R C Benson; K M Tomera; P P Kelalis
Journal:  J Urol       Date:  1983-07       Impact factor: 7.450

10.  Cyclophosphamide, doxorubicin and cisplatin chemotherapy for patients with locally advanced urothelial tumors with or without nodal metastases.

Authors:  C J Logothetis; M L Samuels; S Ogden; F H Dexeus; D Swanson; D E Johnson; A von Eschenbach
Journal:  J Urol       Date:  1985-09       Impact factor: 7.450

View more
  19 in total

1.  Mathematical model of tumor immunotherapy for bladder carcinoma identifies the limitations of the innate immune response.

Authors:  Romulus Breban; Aurelie Bisiaux; Claire Biot; Cyrill Rentsch; Philippe Bousso; Matthew L Albert
Journal:  Oncoimmunology       Date:  2012-01-01       Impact factor: 8.110

2.  Cruciferous vegetables, isothiocyanates, and prevention of bladder cancer.

Authors:  Omkara L Veeranki; Arup Bhattacharya; Li Tang; James R Marshall; Yuesheng Zhang
Journal:  Curr Pharmacol Rep       Date:  2015-08

3.  Diet and bladder cancer: a case-control study.

Authors:  V Radosavljević; S Janković; J Marinković; M Dokić
Journal:  Int Urol Nephrol       Date:  2005       Impact factor: 2.370

4.  Intravenously administered vitamin C as cancer therapy: three cases.

Authors:  Sebastian J Padayatty; Hugh D Riordan; Stephen M Hewitt; Arie Katz; L John Hoffer; Mark Levine
Journal:  CMAJ       Date:  2006-03-28       Impact factor: 8.262

5.  Interleukin-20 promotes migration of bladder cancer cells through extracellular signal-regulated kinase (ERK)-mediated MMP-9 protein expression leading to nuclear factor (NF-κB) activation by inducing the up-regulation of p21(WAF1) protein expression.

Authors:  Se-Jung Lee; Seok-Cheol Cho; Eo-Jin Lee; Sangtae Kim; Soo-Bok Lee; Jung-Hyurk Lim; Yung Hyun Choi; Wun-Jae Kim; Sung-Kwon Moon
Journal:  J Biol Chem       Date:  2012-12-27       Impact factor: 5.157

Review 6.  Quality of life aspects of bladder cancer: a review of the literature.

Authors:  M F Botteman; C L Pashos; R S Hauser; B L Laskin; A Redaelli
Journal:  Qual Life Res       Date:  2003-09       Impact factor: 4.147

7.  Alterations of dendritic cell subsets and TH1/TH2 cytokines in the peripheral circulation of patients with superficial transitional cell carcinoma of the bladder.

Authors:  Feng Lang; Ma Linlin; Tian Ye; Zhang Yuhai
Journal:  J Clin Lab Anal       Date:  2012-09       Impact factor: 2.352

Review 8.  The health economics of bladder cancer: a comprehensive review of the published literature.

Authors:  Marc F Botteman; Chris L Pashos; Alberto Redaelli; Benjamin Laskin; Robert Hauser
Journal:  Pharmacoeconomics       Date:  2003       Impact factor: 4.981

9.  Detection of functional antigen-specific T cells from urine of non-muscle invasive bladder cancer patients.

Authors:  Claire Pieraerts; Virginie Martin; Patrice Jichlinski; Denise Nardelli-Haefliger; Laurent Derre
Journal:  Oncoimmunology       Date:  2012-08-01       Impact factor: 8.110

10.  MicroRNA-23b functions as a tumor suppressor by regulating Zeb1 in bladder cancer.

Authors:  Shahana Majid; Altaf A Dar; Sharanjot Saini; Guoren Deng; Inik Chang; Kirsten Greene; Yuichiro Tanaka; Rajvir Dahiya; Soichiro Yamamura
Journal:  PLoS One       Date:  2013-07-02       Impact factor: 3.240

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.